Certolizumabdat

<p>Data are available from a review of trials of certolizumab pegol (CZP)
for the treatment of rheumatoid arthritis in patients who had failed
on disease-modifying antirheumatic drugs, including methotrexate (MTX). 20
Twelve MTX controlled trials were identified, comparing 6 different
treatments with placebo. The primary outcome is improving by at least 50
of Rheumatology scale (ACR50) at 6 months. A trial-specificc covariate, the mean disease duration
in years for patients, is also given.</p>

datasets

Performs network meta-analysis using integrated nested Laplace approximations ('INLA')
which is described in Guenhan, Held, and Friede (2018) <doi:10.1002/jrsm.1285>.
Includes methods to assess the heterogeneity and inconsistency in the network.
Contains more than ten different network meta-analysis dataset.
'INLA' package can be obtained from <https://www.r-inla.org>.

Burak Kuersad Guenhan

nmaINLA

Network Meta-Analysis using Integrated Nested Laplace
Approximations

Certolizumabdat function

<p>An object of class <code>data.frame</code> with 12 rows and 9 columns.</p>

Certolizumabdat: Data for the Certolizumab NMA-network discussed in Dias et al. (2013)

Description

Usage

Arguments

Format